Citadel Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.83M | Sell |
727,060
-116,133
| -14% | -$978K | ﹤0.01% | 3848 |
|
|
2025
Q4 | $6.86M | Buy |
+843,193
| New | +$10.4M | ﹤0.01% | 3796 |
|
|
2025
Q2 | – | Sell |
-92,991
| Closed | -$676K | – | 12868 |
|
|
2025
Q1 | $494K | Buy |
+92,991
| New | +$821K | ﹤0.01% | 8507 |
|
|
2024
Q3 | – | Sell |
-332,761
| Closed | -$17M | – | 14340 |
|
|
2024
Q2 | $15.1M | Sell |
332,761
-36,406
| -10% | -$1.53M | ﹤0.01% | 2310 |
|
|
2024
Q1 | $14.5M | Buy |
+369,167
| New | +$9.1M | ﹤0.01% | 2438 |
|
|
2023
Q1 | – | Sell |
-230
| Closed | -$762 | – | 14812 |
|
|
2022
Q4 | $762 | Buy |
+230
| New | +$885 | ﹤0.01% | 14586 |
|
|
2022
Q3 | – | Sell |
-2,299
| Closed | -$16.2K | – | 12744 |
|
|
2022
Q2 | $17K | Sell |
2,299
-80
| -3% | -$773 | ﹤0.01% | 12455 |
|
|
2022
Q1 | $38K | Sell |
2,379
-32,498
| -93% | -$431K | ﹤0.01% | 12965 |
|
|
2021
Q4 | $644K | Buy |
34,877
+28,094
| +414% | +$761K | ﹤0.01% | 9045 |
|
|
2021
Q3 | $208K | Buy |
6,783
+1,919
| +39% | +$75.7K | ﹤0.01% | 11906 |
|
|
2021
Q2 | $267K | Sell |
4,864
-1,236
| -20% | -$68.6K | ﹤0.01% | 11547 |
|
|
2021
Q1 | $361K | Buy |
6,100
+2,463
| +68% | +$162K | ﹤0.01% | 10417 |
|
|
2020
Q4 | $136K | Buy |
+3,637
| New | +$136K | ﹤0.01% | 10006 |
|
|
2020
Q3 | – | Sell |
-42,095
| Closed | -$7.62M | – | 10144 |
|
|
2020
Q2 | $10.6M | Sell |
42,095
-3,971
| -9% | -$802K | ﹤0.01% | 2152 |
|
|
2020
Q1 | $7.24M | Buy |
46,066
+45,401
| +6,827% | +$7.68M | ﹤0.01% | 2242 |
|
|
2019
Q4 | $109K | Buy |
+665
| New | +$98.3K | ﹤0.01% | 8511 |
|
|
2019
Q2 | – | Sell |
-4,397
| Closed | -$941K | – | 9246 |
|
|
2019
Q1 | $917K | Buy |
4,397
+501
| +13% | +$110K | ﹤0.01% | 5739 |
|
|
2018
Q4 | $683K | Buy |
3,896
+2,657
| +214% | +$530K | ﹤0.01% | 5920 |
|
|
2018
Q3 | $281K | Sell |
1,239
-247
| -17% | -$39.9K | ﹤0.01% | 7675 |
|
|
2018
Q2 | $226K | Buy |
1,486
+770
| +108% | +$140K | ﹤0.01% | 7677 |
|
|
2018
Q1 | $131K | Buy |
716
+104
| +17% | +$23.4K | ﹤0.01% | 7607 |
|
|
2017
Q4 | $130K | Buy |
+612
| New | +$131K | ﹤0.01% | 7327 |
|
|
2017
Q3 | – | Sell |
-810
| Closed | -$158K | – | 7589 |
|
|
2017
Q2 | $153K | Buy |
810
+213
| +36% | +$41.8K | ﹤0.01% | 6724 |
|
|
2017
Q1 | $148K | Buy |
+597
| New | +$147K | ﹤0.01% | 6691 |
|
|
2016
Q3 | – | Sell |
-356
| Closed | -$32K | – | 7286 |
|
|
2016
Q2 | $32K | Buy |
+356
| New | +$27.9K | ﹤0.01% | 6508 |
|
|
2016
Q1 | – | Sell |
-342
| Closed | -$17K | – | 6935 |
|
|
2015
Q4 | $17K | Buy |
+342
| New | +$17.4K | ﹤0.01% | 8042 |
|
Other funds holding CRBP
CAM
O
VCM
PM
DP
SCM
AC
Citadel Advisors's CRBP Position: Q1 2026 in Review
Citadel Advisors reduced its Corbus Pharmaceuticals (CRBP) stake by 14% in Q1 2026, selling an estimated $978K and leaving 727,060 shares worth $6.83M. The position accounts for ﹤0.01% of the portfolio, ranked #3848.
Citadel Advisors first reported a position in CRBP in Q4 2015 and has held it in 26 quarters since. The position peaked at $15.1M in Q2 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.
- Citadel Advisors held 727,060 shares of Corbus Pharmaceuticals worth $6.83M as of Q1 2026.
- Citadel Advisors sold 116,133 Corbus Pharmaceuticals shares in Q1 2026, an estimated $978K.
- Corbus Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3848 holding.
- Citadel Advisors first reported a position in Corbus Pharmaceuticals in Q4 2015 and has held it in 26 quarters since.
- Citadel Advisors's Corbus Pharmaceuticals position peaked at $15.1M in Q2 2024.
- 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.